Drug Interactions between brimonidine / dorzolamide / latanoprost / timolol ophthalmic and methylene blue
This report displays the potential drug interactions for the following 2 drugs:
- brimonidine/dorzolamide/latanoprost/timolol ophthalmic
- methylene blue
Interactions between your drugs
methylene blue brimonidine ophthalmic
Applies to: methylene blue and brimonidine / dorzolamide / latanoprost / timolol ophthalmic
MONITOR: Topically administered alpha-2 adrenergic receptor agonists such as brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. Despite relative alpha-2 selectivity, theoretical concerns exist that coadministration with monoamine oxidase inhibitors (MAOIs) may increase the risk of hypertension due to potentiation of alpha-1 stimulation, which produces vasoconstriction. MAOIs may also theoretically interfere with the metabolism of brimonidine, which may result in increased systemic adverse effects such as drowsiness, dizziness, lightheadedness, hypotension, and bradycardia. However, an interaction with MAOIs has not been reported in the medical literature.
MANAGEMENT: Patients receiving brimonidine in combination with MAOIs should be made aware of the potential for increased adverse effects, and counseled to avoid activities requiring mental alertness until they know how these agents affect them. Patients should also avoid rising abruptly from a sitting or recumbent position and notify their physician if they experience orthostasis or tachycardia. Blood pressure should be monitored closely.
References (12)
- Pettinger WA, Soyangco FG, Oates JA (1968) "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther, 9, p. 442-7
- Schulz R, Antonin KH, Hoffmann E, et al. (1989) "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther, 46, p. 528-36
- Goldberg LI (1964) "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA, 190, p. 456-62
- King MH, Richards DW (1990) "Near syncope and chest tightness after administration of apraclonidine before argon laser iridotomy." Am J Ophthalmol, 110, p. 308-9
- Coleman AL, Robin AL, Pollack IP, Rudikoff MT, Enger C, Mayer PR (1990) "Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine." Arch Ophthalmol, 108, p. 1264-7
- "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc
- De Vita VT, Hahn MA, Oliverio VT (1965) "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med, 120, p. 561-5
- Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH (1983) "Blood pressure effects of phenelzine." J Clin Psychopharmacol, 3, p. 307-10
- Nordlund JR, Pasquale LR, Robin AL, Rudikoff MT, Ordman J, Chen KS, Walt J (1995) "The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine." Arch Ophthalmol, 113, p. 77-83
- (2001) "Product Information. Alphagan (brimonidine ophthalmic)." Allergan Inc
- Pekdemir M, Yanturali S, Karakus G (2005) "More than just an ocular solution." Emerg Med J, 22, p. 753-4
- (2013) "Product Information. Mirvaso (brimonidine topical)." Galderma Laboratories Inc
timolol ophthalmic brimonidine ophthalmic
Applies to: brimonidine / dorzolamide / latanoprost / timolol ophthalmic and brimonidine / dorzolamide / latanoprost / timolol ophthalmic
MONITOR: Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects such as hypotension and bradycardia. The possibility for an additive or potentiating effect on blood pressure and heart rate should be considered when used with other medications that affect these parameters, such as ophthalmic and systemic beta blockers, vasodilators, cardiac glycosides, and antihypertensive agents.
MANAGEMENT: Blood pressure and pulse rate should be monitored regularly when topical alpha-2 adrenergic receptor agonists are prescribed in combination with cardiovascular drugs. Patients should be advised to notify their physician if they experience slow pulse, irregular heartbeat, dizziness, lightheadedness, or syncope.
References (7)
- King MH, Richards DW (1990) "Near syncope and chest tightness after administration of apraclonidine before argon laser iridotomy." Am J Ophthalmol, 110, p. 308-9
- "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc
- Nordlund JR, Pasquale LR, Robin AL, Rudikoff MT, Ordman J, Chen KS, Walt J (1995) "The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine." Arch Ophthalmol, 113, p. 77-83
- (2001) "Product Information. Alphagan (brimonidine ophthalmic)." Allergan Inc
- Walters TR (1996) "Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies." Surv Ophthalmol, 41 ( Suppl, s19-26
- Pekdemir M, Yanturali S, Karakus G (2005) "More than just an ocular solution." Emerg Med J, 22, p. 753-4
- (2013) "Product Information. Mirvaso (brimonidine topical)." Galderma Laboratories Inc
Drug and food interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.